Roche Acquires Cancer Immunotherapy Developer Tusk Therapeutics

Roche has acquired Tusk Therapeutics for up to €655 million ($759 million), Tusk said, in a deal that expands the buyer’s oncology pipeline with two preclinical first-in-class antibodies set to advance into the clinic next year.Based at the Stevenage Bioscience Catalyst in Stevenage, U.K., privately-held Tusk is a developer of immuno-oncology treatments focused on discovering and developing therapeutic antibodies.Tusk is developing a first-in-class anti-CD25 antibody designed to deple